Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of	
L. Montagnier et al	
Application Number	**Filed**
06/706 562	2/28/85
Group Art Unit	**Examiner**

Paper No. _____

RECEIVED

NOV 2 4 1999

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

___ (A) referred to in United States Patent Number 5843638, column _____

___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____ filed _____, on page _____ of paper number _____.

___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____ filed: _____, or

___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

_____

_____

_____

Cantwell & Layton
Signature

11/ /99
Date

_____
Typed or printed name

FOR PTO USE ONLY

Approved by: _____
(Initials)

Unit: _____

Time will vary depending upon the needs of the [illegible]. This form should be sent to the Chief Information Officer [illegible]. SEND FORMS TO THIS ADDRESS [illegible]

US005843638A

United States Patent [19]

Montagnier et al.

[11] Patent Number: 5,843,638

[45] Date of Patent: Dec. 1, 1998

[54] NUCLEIC ACIDS AND PEPTIES OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1).

[75] Inventors: **Luc Montagnier**, Le Plessis Robinson; **Bernard Krust**; **Solange Chamaret**, both of Paris; **François Clavel**, Paris; **Jean-Claude Chermann**, Elancourt; **Françoise Barre-Sinoussi**, Issy les Moulineaux; **Marc Alizon**; **Pierre Sonigo**, both of Paris; **Stewart Cole**, Chatillon; **Olivier Danos**, Paris; **Simon Wain-Hobson**, Montigny les Bretonneux, all of France

[73] Assignee: **Institut Pasteur and Centre National de la Recherche Scientifique**, Paris, France

[21] Appl. No.: **468,387**

[22] Filed: **Jun. 6, 1995**

Related U.S. Application Data

[60] Continuation of Ser. No. 130,565, Oct. 1, 1993, abandoned, which is a division of Ser. No. 970,954, Nov. 3, 1992, abandoned, which is a continuation of Ser. No. 747,506, Aug. 20, 1991, abandoned, which is a continuation of Ser. No. 622,278, Dec. 6, 1990, abandoned, which is a continuation of Ser. No. 390,499, Aug. 1, 1989, abandoned, which is a continuation of Ser. No. 920,119, Oct. 17, 1986, abandoned, which is a continuation-in-part of Ser. No. 771,248, Aug. 30, 1985, abandoned, which is a continuation-in-part of Ser. No. 771,247, Sep. 30, 1985, abandoned, which is a continuation-in-part of Ser. No. 771,230, Aug. 30, 1985, abandoned, which is a continuation-in-part of Ser. No. 706,562, Feb. 28, 1985, abandoned, which is a continuation-in-part of Ser. No. 558,109, Dec. 5, 1983, abandoned.

[30] **Foreign Application Priority Data**

Nov. 16, 1984 [GB] United Kingdom 84 29099
Oct. 18, 1985 [CA] Canada 493377

[51] **Int. Cl.**[6] **C12Q 1/70**; C12Q 1/68; C12N 15/49; C07H 21/04

[52] **U.S. Cl.** **435/5**; 435/7; 435/9; 435/69.1; 435/320.1; 536/23.1; 536/24.3

[58] **Field of Search** 435/5, 7, 69.1, 435/320.1; 536/23.1, 24.3

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,725,669 2/1988 Essex et al. 435/5
5,165,949 11/1992 Luciw et al. 435/5

FOREIGN PATENT DOCUMENTS

0 138 667 4/1985 European Pat. Off. .

OTHER PUBLICATIONS

Montagnier, et al., "Identification and Antigenicity of the Major Envelope Glycoprotein of Lymphadenopathy–Associated Virus," *Virology 144*–283–289 (1985).

Barin et al., "Virus Envelope Protein of HTLV–III Represents Major Target Antigen for Antibodies in AIDS Patients," *Science, 228,* 1094–1096 (1985).

Allan et al., "Major Glycoprotein Antigens That Induce Antibodies in AIDS Patients Are Encoded by HTLV–III," *Science, 228,* 1091–1094 (1985).

Pauletti et al., "Application of a Modified Computer Algorithm in Determining Potential Antigenic Determinants Associated with the AIDS Virus Glycoprotein," *Analytical Biochemistry, 151,* 540–546 (1985).

Sarngadharan et al., "Immunological Properties of HTLV–III Antigens Recognized by Sera of Patients with AIDS and AIDS–Related Complex and of Asymptomatic Carriers of HTLV–III Infection " *Cancer Research, 45,*4574s–4577s (1985).

Robey et al., "Characterization of Envelope and Core Structual Gene Products of HTLV–III with Sera from AIDS Patients," *Science, 228,* 593–595 (1985).

Wain–Hobson et al., "Nucleotide Sequence of the AIDS Virus, LAV,"*Cell, 40,* 9–17 (1985).

Muesing et al., "Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus," *Nature, 313,* 450–458 (1985).

Sanchez–Pescador et al., "Nucleotide Sequence and Expression of an AIDS–Associated Retrovirus (ARV–2)," *Science, 227,* 484–492 (1985).

Ratner et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV–III," *Nature, 313,*277–284 (1985).

Chang et al., "An HTLV–III Peptide Produced By Recombinant DNA is Immunoreactive with Sera from Patients with AIDS," *Nature, 315,* 151–154 (1985).

Dowbenko et al., "Bacterial Expression of the Acquired Immunodeficiency Syndrome Retrovirus p24 gag Protein and its use as a Diagnostic Reagent," *Proc. Natl. Acad. Sci. USA, 82,* 7748–7752 (1985).

Chang et al., "Detection of Antibodies to Human T–Cell Lymphotropic Virus–III (HTLV–III) with an Immunoassay Employing a Recombinant *Escherichia coli*–Derived Viral Antigenic Peptide," *Bio/Technology, 3* 905–909 (1985).

Chang et al., "Expression in *Escherichia coli* of Open Reading Frame Gene Segments of HTLV–III," *Science, 228,* 93–96 (1985).

Schneider et al., "A Glycopolypeptide (gp 100) is the Main Antigen Detected By HTLV–III Antisera," *Med. Mircrobiol. Immunol., 174,* 35–42 (1985).

Primary Examiner—Michael P. Woodward
Assistant Examiner—Mary K. Zeman
Attorney, Agent, or Firm—Finnegan, Henderson, Farabow, Garrett & Dunner

[57] **ABSTRACT**

This invention is directed to nucleic acids derived from the pol region of the genome of human immunodeficiency virus type 1 (HIV-1). The nucleic acids are useful as probes for the detection of HIV-1. More particularly, this invention is directed to nucleic acids encoding a pol region of HIV-1 extending from about nucleotide 1856 to about 1906 and extending from about nucleotide 2048 to about nucleotide 2797.

1 Claim, 12 Drawing Sheets